Calithera Biosciences, Inc. Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company, today announced the pricing of its initial public offering of 8,000,000 shares of common stock at a price of $10.00 per share. The common stock of Calithera Biosciences, Inc. has been approved for listing on the NASDAQ Global Select Market and is expected to begin trading under the ticker symbol "CALA" on October 2, 2014. All of the common stock is being offered by Calithera Biosciences, Inc. In addition, Calithera Biosciences, Inc. has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock.

Citigroup and Leerink Partners are acting as joint book-running managers for the offering. Wells Fargo Securities and JMP Securities are acting as co-managers for the offering.

The offering will be made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained, when available, from Citigroup Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at [email protected] or by telephone at (800) 831-9146 or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at [email protected], or by telephone at (800) 808-7525, ext. 4814.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and declared effective on October 1, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.

CONTACT: Investor Contact: Jennifer McNealey Calithera[email protected] 650-870-1071 Media Contact: BCC Partners Karen L. Bergman or Michelle Corral [email protected] 650.575.1509[email protected] 415.794.8662

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.